89bio appoints Martin Babler, a 30+ year pharma/biotech executive, to its Board of Directors to aid in late-stage development and commercialization of pegozafermin.
89bio, a biopharmaceutical firm focused on liver & cardiometabolic diseases, announces the appointment of Martin Babler to its Board of Directors. Babler, a seasoned executive with 30+ years in pharma & biotech, will aid 89bio in advancing its lead program, pegozafermin, through late-stage development & plans for commercialization. Babler has previously held leadership roles at Genentech, Principia Biopharma, and Talima Therapeutics.
April 17, 2024
3 Articles